Intrinsic Value of S&P & Nasdaq Contact Us
English English 中文(简) 中文(简) 中文(繁) 中文(繁) हिन्दी हिन्दी Español Español 日本語 日本語 한국어 한국어 Deutsch Deutsch Français Français
← Back to all stocks

Kaleido Biosciences, Inc. KLDO OTC

Other OTC • Healthcare • Biotechnology • US • USD

SharesGrow Score
20/100
0/5 Pass
SharesGrow Intrinsic Value
N/A
Negative cash flow

Kaleido Biosciences, Inc. (KLDO) is a Biotechnology company in the Healthcare sector, currently trading at $0.00. It has a SharesGrow Score of 18/100, indicating a weak investment profile with 0 out of 7 criteria passed.

Net profit margin is 0% (thin). Gross margin is -113.6% (-207.9 pp trend).

Balance sheet: total debt is $0 against $0 equity. Total assets: $0.

Analyst outlook: 4 / 7 analysts rate KLDO as buy (57%) — moderate consensus.

SharesGrow 7-Criteria breakdown: Value ?/100 (Fail), Growth 58/100 (Partial), Past 0/100 (Fail), Health 0/100 (Fail), Moat 0/100 (Fail), Future 40/100 (Partial), Income ?/100 (Fail).

KLDO SharesGrow Score Overview

49/100
SharesGrow Score
Mixed signals — some strengths
View full scorecard →
VALUE 0/100
Valuation — P/E, PEG, Forward PEG
GROWTH 58/100
Financials — average growth
PAST 0/100
strong — trend
HEALTH 0/100
Balance sheet — Debt-to-Equity (D/E) ratio, Current ratio is
MOAT 0/100
Gross margin is + market cap
FUTURE 40/100
Analyst outlook — as buy
INCOME 0/100
Net profit margin is
Scores derived from financial statements, analyst ratings, and balance sheet data.

Score Breakdown — KLDO

—
VALUE N/A
N/A
No analyst coverage available for this stock.
~
GROWTH Partial
58/100
KLDO: -43.4%/yr revenue is, +29.7%/yr Net income is average growth. mixed. Score: >20%/yr = 100, >10% = 80, >5% = 65, >0% = 45, < 0 = 15.
View details →
—
PAST N/A
N/A
No analyst coverage available for this stock.
—
HEALTH N/A
N/A
No analyst coverage available for this stock.
—
MOAT N/A
N/A
No analyst coverage available for this stock.
~
FUTURE Partial
40/100
Analyst outlook: 4 / 7 analysts rate KLDO as buy (57%). Score: 60% buy consensus + 40% upside. ≥ 60 = Pass.
View details →
—
INCOME N/A
N/A
No analyst coverage available for this stock.

Stock Chart & Stats

Market Data
52-Week Range0.00001-0.19
Volume3.19K
Avg Volume (30D)1.12K
Market Cap$4.26K
Beta (1Y)-1.17
Share Statistics
IPO Date2019-02-28
Employees76
CEOMark A. Wingertzahn
Financial Highlights & Ratios
Analyst Forecast
Rating ConsensusBuy
Analysts Covering7
Buy 57% Hold 29% Sell 14%
Company Info
CountryUS
ExchangeOther OTC
CurrencyUSD
ISINUS4833471000

Price Chart

Track all markets on TradingView
KLDO
Kaleido Biosciences, Inc. ↗  ·  Other OTC
Healthcare • Biotechnology
0.00 52WK RANGE 0.19

People Also View

NUVB
NUVB
Nuvation Bio Inc.
$4.85
+3.19%
 CTMX
CTMX
CytomX Therapeutics, Inc.
$4.54
+3.42%
 ASMB
ASMB
Assembly Biosciences, Inc.
$29.44
+0.68%
 IKT
IKT
Inhibikase Therapeutics, Inc.
$1.70
-0.58%
 TIL
TIL
Instil Bio, Inc.
$8.44
+1.02%
 CRPOF
CRPOF
Ceapro Inc.
$0.17
-13.04%
 AMTI
AMTI
Applied Molecular Transport Inc.
$0.26
-3.13%
 TPST
TPST
Tempest Therapeutics, Inc.
$2.25
+5.14%
Contact Us
🎓
SharesGrow Academy
Learn how to calculate Intrinsic Value and find undervalued stocks.
Weekly live sessions
📧 [email protected]
📞 +65 8912 8000
Send us a message